Changes in Hong Kong stocks | CSPC Group (01093) rose more than 3% at the end of the session, the second listing license application for simeglutide injection was accepted

The Zhitong Finance App learned that CSPC Group (01093) rose more than 3% at the end of the session. As of press release, it had risen 2.92% to HK$7.75, with a turnover of HK$515 million.

According to the news, on December 8, CSPC Group announced that the second marketing license application for the simeglutide injection developed by the company's subsidiary Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd. has been accepted by the State Drug Administration of the People's Republic of China. The indication for this report is long-term weight management for adult overweight/obese patients based on diet control and increased physical activity. Previously, the marketing license application for this product intended for use in adult type 2 diabetes blood sugar control was accepted by the State Drug Administration in August 2025.

According to the announcement, the application is based on a phase III clinical trial. The clinical trial results showed that in non-diabetic obese adult subjects, the product can significantly reduce body weight and waist circumference and improve blood sugar, blood fat and liver enzyme levels; compared with the simeglutide developed by Novo Nordisk, its efficacy is highly consistent, the safety characteristics are similar, and the incidence of adverse events is slightly lower. Based on its advantages in efficacy, safety and formulation, the product has significant clinical application value.